Global Markets Direct’s, ‘Klebsiella Pneumoniae Infections – Pipeline Review, H2 2015′, provides an overview of the Klebsiella Pneumoniae Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Klebsiella Pneumoniae Infections
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Klebsiella Pneumoniae Infections and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Klebsiella Pneumoniae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Klebsiella Pneumoniae Infections pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Klebsiella Pneumoniae Infections
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Klebsiella Pneumoniae Infections pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Klebsiella Pneumoniae Infections Overview 10
Therapeutics Development 11
Pipeline Products for Klebsiella Pneumoniae Infections - Overview 11
Pipeline Products for Klebsiella Pneumoniae Infections - Comparative Analysis 12
Klebsiella Pneumoniae Infections - Therapeutics under Development by Companies 13
Klebsiella Pneumoniae Infections - Therapeutics under Investigation by Universities/Institutes 15
Klebsiella Pneumoniae Infections - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Klebsiella Pneumoniae Infections - Products under Development by Companies 18
Klebsiella Pneumoniae Infections - Products under Investigation by Universities/Institutes 21
Klebsiella Pneumoniae Infections - Companies Involved in Therapeutics Development 22
Arsanis Biosciences GmbH 22
Boehringer Ingelheim GmbH 23
Cellceutix Corporation 24
Debiopharm International S.A. 25
Evaxion Biotech 26
F. Hoffmann-La Roche Ltd. 27
FOB Synthesis, Inc. 28
Melinta Therapeutics, Inc 29
Merck & Co., Inc. 30
MicuRx Pharmaceuticals, Inc. 31
Nosopharm SAS 32
Novan, Inc. 33
Pfizer Inc. 34
Phico Therapeutics Limited 35
Procarta Biosystems Ltd 36
Sarepta Therapeutics, Inc. 37
Shionogi & Co., Ltd. 38
Soligenix, Inc. 39
Sumitomo Dainippon Pharma Co., Ltd. 40
Syntiron LLC 41
Tetraphase Pharmaceuticals Inc. 42
Theraclone Sciences, Inc. 43
Trana Discovery, Inc. 44
Klebsiella Pneumoniae Infections - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Target 46
Assessment by Mechanism of Action 48
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ASN-300 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
CB-027 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CB-618 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
CC-1807 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CTIX-1278 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Debio-1454 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
dusquetide - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
FSI-1671 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
FSI-1686 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
GN snare - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
IBN-1 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Klebsiella pneumoniae vaccine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Klebsiella pneumoniae vaccine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Monoclonal Antibody for Klebsiella Pneumoniae Infections - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
MRX-V - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
NOSO-95179 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
NVN-1000 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Onc-72 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
pneumonia vaccine - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
PT-4 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
PXS-4728A - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
RX-05 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
RXP-792 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
RXP-873 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
S-649266 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
SM-295291 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
SM-369926 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Small Molecules for Klebsiella pneumoniae Infections - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Synthetic Peptide for Klebsiella Pneumoniae Infections - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
TP-076 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
TP-138 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
TP-600 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
TP-6076 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Klebsiella Pneumoniae Infections - Recent Pipeline Updates 97
Klebsiella Pneumoniae Infections - Dormant Projects 103
Klebsiella Pneumoniae Infections - Discontinued Products 104
Klebsiella Pneumoniae Infections - Product Development Milestones 105
Featured News & Press Releases 105
Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae towards Clinical Trials 105
Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-027 At ICAAC 2012 105
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 106
Disclaimer 107

List of Tables

Number of Products under Development for Klebsiella Pneumoniae Infections, H2 2015 11
Number of Products under Development for Klebsiella Pneumoniae Infections - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Development by Companies, H2 2015 (Contd..1) 19
Products under Development by Companies, H2 2015 (Contd..2) 20
Products under Investigation by Universities/Institutes, H2 2015 21
Klebsiella Pneumoniae Infections - Pipeline by Arsanis Biosciences GmbH, H2 2015 22
Klebsiella Pneumoniae Infections - Pipeline by Boehringer Ingelheim GmbH, H2 2015 23
Klebsiella Pneumoniae Infections - Pipeline by Cellceutix Corporation, H2 2015 24
Klebsiella Pneumoniae Infections - Pipeline by Debiopharm International S.A., H2 2015 25
Klebsiella Pneumoniae Infections - Pipeline by Evaxion Biotech, H2 2015 26
Klebsiella Pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 27
Klebsiella Pneumoniae Infections - Pipeline by FOB Synthesis, Inc., H2 2015 28
Klebsiella Pneumoniae Infections - Pipeline by Melinta Therapeutics, Inc, H2 2015 29
Klebsiella Pneumoniae Infections - Pipeline by Merck & Co., Inc., H2 2015 30
Klebsiella Pneumoniae Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2015 31
Klebsiella Pneumoniae Infections - Pipeline by Nosopharm SAS, H2 2015 32
Klebsiella Pneumoniae Infections - Pipeline by Novan, Inc., H2 2015 33
Klebsiella Pneumoniae Infections - Pipeline by Pfizer Inc., H2 2015 34
Klebsiella Pneumoniae Infections - Pipeline by Phico Therapeutics Limited, H2 2015 35
Klebsiella Pneumoniae Infections - Pipeline by Procarta Biosystems Ltd, H2 2015 36
Klebsiella Pneumoniae Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2015 37
Klebsiella Pneumoniae Infections - Pipeline by Shionogi & Co., Ltd., H2 2015 38
Klebsiella Pneumoniae Infections - Pipeline by Soligenix, Inc., H2 2015 39
Klebsiella Pneumoniae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 40
Klebsiella Pneumoniae Infections - Pipeline by Syntiron LLC, H2 2015 41
Klebsiella Pneumoniae Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015 42
Klebsiella Pneumoniae Infections - Pipeline by Theraclone Sciences, Inc., H2 2015 43
Klebsiella Pneumoniae Infections - Pipeline by Trana Discovery, Inc., H2 2015 44
Assessment by Monotherapy Products, H2 2015 45
Number of Products by Stage and Target, H2 2015 47
Number of Products by Stage and Mechanism of Action, H2 2015 49
Number of Products by Stage and Route of Administration, H2 2015 51
Number of Products by Stage and Molecule Type, H2 2015 53
Klebsiella Pneumoniae Infections Therapeutics - Recent Pipeline Updates, H2 2015 97
Klebsiella Pneumoniae Infections - Dormant Projects, H2 2015 103
Klebsiella Pneumoniae Infections - Discontinued Products, H2 2015 104

List of Figures

Number of Products under Development for Klebsiella Pneumoniae Infections, H2 2015 11
Number of Products under Development for Klebsiella Pneumoniae Infections - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Products, H2 2015 17
Assessment by Monotherapy Products, H2 2015 45
Number of Products by Top 10 Targets, H2 2015 46
Number of Products by Stage and Top 10 Targets, H2 2015 46
Number of Products by Top 10 Mechanism of Actions, H2 2015 48
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 48
Number of Products by Routes of Administration, H2 2015 50
Number of Products by Stage and Routes of Administration, H2 2015 50
Number of Products by Molecule Types, H2 2015 52
Number of Products by Stage and Molecule Types, H2 2015 52